×
Home
About
Disclaimer
Privacy
JCS/T2D - We are advocates. We learn. We share. We inform.
Enter Part of Title
Display #
5
10
15
20
25
30
50
100
All
2025 Outlook: GLP-1 Supply Gains Momentum Amid Expansion Efforts
Eli Lilly and Novo Nordisk Invest in Increased Manufacturing Capacity for GLP-1 Drugs
Eli Lilly and Novo Nordisk Ramp Up GLP-1 Manufacturing Capacity
Eli Lilly Narrows Focus for Oral GLP-1 Naperiglipron
Eli Lilly's Once-Weekly Insulin Efsitora Alfa Shows Positive Phase 3 Results
Eli Lilly's Stance on Tirzepatide for Cosmetic Use
Eli Lilly's Tirzepatide Shows Promise in Phase 3 Trial for Heart Failure and Obesity
Eli Lilly’s Tirzepatide Shows Promising Results in MASH Treatment
Exploring the Potential of Tirzepatide for Obstructive Sleep Apnea: A New Horizon in Treatment
FDA Approves Zepbound for Obstructive Sleep Apnea in Adults with Obesity
FDA Reconsiders Tirzepatide Shortage Status
Lilly Adds High-Dose Zepbound to Self-Pay Program, Expands Access to All Approved Strengths
Lilly Advances Orforglipron Toward Approval After Third Phase 3 Win
Lilly Expands Zepbound Access with Single-Dose Vials at Half Price
Lilly's Three-Year SURMOUNT-1 Data Demonstrates Tirzepatide’s Role in Diabetes Prevention
Lilly’s Oral GLP-1 Clears Key Trial as Pfizer Exits Race
Lilly’s Oral GLP-1 Falls Short of Expectations, Boosting Novo Nordisk
Lilly’s Oral GLP-1 Outperforms Farxiga in Type 2 Diabetes Trial
Lilly’s Oral GLP-1 Pill Shows Strong Phase 3 Results as Novo Submits Rival for FDA Approval
Lilly’s Oral GLP-1, Orforglipron, Shows Strong Results in Obesity and Diabetes Trials
Page 1 of 2
1
2
Articles
Articles
All News
News
October 2025
FDA Approves Novo Nordisk’s Oral Semaglutide for Heart Protection in Type 2 Diabetes
Lilly’s Oral GLP-1 Outperforms Farxiga in Type 2 Diabetes Trial
September 2025
Novo Nordisk Resubmits Once-Weekly Basal Insulin Awiqli® for FDA Review
Dexcom Introduces Smart Basal at EASD 2025
Novo Nordisk Survey Links Wegovy® to Reduced “Food Noise” and Improved Well-Being
Lilly’s Oral GLP-1, Orforglipron, Shows Strong Results in Obesity and Diabetes Trials
Novonesis and Novo Nordisk Launch Gut Microbiome Collaboration
CVS Caremark Faces Lawsuit Over Dropping Zepbound
Eli Lilly Narrows Focus for Oral GLP-1 Naperiglipron
August 2025
Wegovy Outperforms Mounjaro in Cardiovascular Outcomes
Teva Launches First Generic GLP-1 for Obesity
Novo Nordisk Strikes $550M RNA Deal with Replicate Bioscience
FDA Expands Repatha Access to More High-Risk Adults
Lilly Advances Orforglipron Toward Approval After Third Phase 3 Win
Signos Press Release Raises Questions About FDA Clearance Claims
Novo Nordisk Expands $499 Cash-Pay Option to Ozempic
FDA Approves Wegovy for MASH Treatment
Lilly’s Oral GLP-1 Falls Short of Expectations, Boosting Novo Nordisk
July 2025
Mounjaro Shows Heart Health Potential in Landmark Diabetes Trial
Novo Nordisk Lowers Outlook, Names New CEO, and Restructures R&D
Contact Us
How many eyes does a typical person have?
Search
Search
You are here:
Home
JCS/T2D - A Diabetes Journey
